Abstract: A computer implemented system for determining an overall-classifier for one or more source-histological-images. The system comprising: a first tile generator (204) configured to generate a plurality of first-tiles (206; 306) from the one or more source-histological-image (202; 302); and a second tile generator (205) configured to generate a plurality of second-tiles (207; 307) from the one or more source-histological-images (202; 302). The first-area of the first-tiles (206; 306) is larger than the second-area of the second-tiles (207; 307); and the second-resolution of the second-tiles (207; 307) is higher than the first-resolution of the first-tiles (206; 306).

Abstract: Chimeric antigen receptors (CARs) are provided. When the CARs herein are expressed on the surface of immune cells, such immune cells may be directed to osteosarcoma cells. In a murine intraperitoneal model, the tumor growth was significantly delayed for T cells expressing a CAR comprising a scFv from TP1 or TP3 antibodies. Immune cells expressing the CARs herein display therapeutic effect in the form of decreased tumor volume in a murine model simulating metastatic osteosarcoma. Combined with the finding that stem cells from healthy bone marrow were not significantly affected by T cells expressing any of the CARs, the CARs may be used for the treatment of osteosarcoma.

Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of heterodimer vaccine molecules formed from monomers comprising a targeting unit and a variant antigenic unit joined by heterodimerization units.

Abstract: A method of forecasting transport of a region of plasma density enhancement within a polar region is provided. The method comprises: providing a convection model for predicting electrostatic potential distribution within the polar region over time; determining the total electron content distribution within the polar region; and determining whether reconnection is occurring. If reconnection is determined to be occurring, the method comprises: identifying a region of plasma density enhancement using the total electron content distribution; and calculating a velocity of at least a portion of the plasma density enhancement using the convection model, such that transport of a region of plasma density enhancement over time can be forecast.

Abstract: The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: (I) in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents a mitotropic moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply-sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.

Abstract: A peptide mixture suitable for eliciting an immune response, comprising a first peptide and a second peptide. The first peptide comprises a first sequence of at least (8) amino acids, wherein said first sequence has at least 75% sequence identity to a first region of (8) amino acids of SEQ ID NO: 11. This first region includes position (201) of the SEQ ID NO: 11 such that the first sequence includes the amino acid in position (201) of the SEQ ID NO: 11. The second peptide comprises a second sequence of at least (8) amino acids, wherein said second sequence has at least 75% sequence identity to a second region of (8) amino acids of SEQ ID NO: 12. This second region includes position (201) of the SEQ ID NO: 12 such that the second sequence includes the amino acid in position (201) of the SEQ ID NO: 12.

Abstract: The present invention provides a nucleic acid molecule encoding a specific binding molecule capable of binding an h TERT peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 when the peptide is presented by a Class II Major Histocompatibility Complex (MHC), wherein the specific binding molecule comprises a first polypeptide comprising a variable region of an ?-chain and a second polypeptide comprising a variable region of a ?-chain of a T-cell receptor (TCR), and wherein: (a) the variable region of an ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4; and (b) the variable region of a ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the sequences set forth in SEQ ID NOs: 5, 6 and 7. Recombinant constructs, vectors and host cells comprising such nucleic acid molecules are also provided, as are specific binding molecules encoded by such nucleic acid molecules.

Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.

Abstract: A machine learning algorithm is trained on a number of microscopic images and a measure of outcome of each image. Each image is divided into tiles. The measure of outcome is assigned to each tile of the image. The tiles are then used to train the machine learning algorithm. The trained algorithm may then be used to evaluate images.

Abstract: There is provided a sensor device, a sensor module, and methods for determining a position of a light source. The sensor device comprises a plurality of sensor units, each sensor unit having a respective sensor area. The sensor device also comprises a mask disposed above the plurality of sensor units and arranged such that incident light from the light source will illuminate different regions of the sensor area of each one of the sensor units depending on the position of the light source relative to the sensor device. The position of the light source may therefore be determined based on which regions of the sensor area of the sensor units are illuminated. Further, each sensor unit is arranged to be controlled by a respective unit controller to determine the position of the light source.

Abstract: The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g.

Abstract: Provided herein is a leukocyte tyrosine kinase (LTK) inhibitor for use in the treatment of a viral infection in a subject, wherein the viral infection is caused by an RNA virus. Also provided are methods of treating a viral infection in a subject, wherein the viral infection is caused by an RNA virus, the method comprising administering to the subject an LTK inhibitor, and the use of an LTK inhibitor in the manufacture of a medicament for the treatment of a viral infection, wherein the viral infection is caused by an RNA virus. In particular, the infection may be an influenza or coronavirus infection in a human subject.

Abstract: Aspects of the disclosure relate generally to computer software and musical gameplay elements. More specifically, aspects of the disclosure provide a method of using multiple musical tracks of varying intensity based on well-timed user inputs and/or player advancement in a rhythm-based video game. Other aspects of the disclosure relate to techniques to improve player on beat inputs in a rhythm-based video game.

Abstract: Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.

Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: Provided and described herein is the use of an oligomeric protein as a binding agent for binding to lipopolysaccharide (LPS), the oligomeric protein having a coiled coil structure comprising at least two monomer peptides, wherein each monomer peptide, which may be the same or different, is capable of forming an ?-helix and comprises at least one core sequence having at least 60% sequence identity to the heptad repeat sequence of SEQ ID NO. 1. Also provide and described herein are methods of binding, detecting and removing LPS, and products comprising the oligomeric protein.

Abstract: The present invention provides a polypeptidic compound for use in prevention or treatment of cardiac remodeling in a subject, the polypeptidic compound comprising the amino acid sequence of proANP31-67, or an amino acid sequence having at least 80% sequence identity thereto.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.